Category: Biology

  • Colossal Biosciences Eyes $20 Billion Valuation as De-Extinction Efforts Gain Investor Momentum

    Colossal Biosciences Eyes $20 Billion Valuation as De-Extinction Efforts Gain Investor Momentum

    Colossal Biosciences, the U.S. biotechnology company working to resurrect extinct species such as the woolly mammoth and the dire wolf, is reportedly in talks to raise new capital at a valuation of at least $20 billion. According to a report by Axios, the funding round could value the Dallas-based startup between $20 billion and $30 billion, nearly doubling its $10.2 billion valuation from early 2025. While the lead investor has not been disclosed, discussions have been ongoing for months and are said to be nearing completion.

    From Ambitious Science to Commercial Growth

    Founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal is known for its “de-extinction” technology, which uses gene-editing techniques to recreate the traits of species that vanished thousands of years ago. Unlike its previous funding round when the company was pre-revenue, Colossal is now generating income — a significant shift in its business model. Investors view its technology as applicable beyond wildlife conservation, extending to pharmaceuticals, biodiversity preservation, climate adaptation, and longevity research.

    Recently, Colossal announced it had successfully hatched chicks from artificial eggs, a step toward reviving the extinct giant moa bird. CEO Ben Lamm has stated that the company plans to develop an artificial womb for mammals within the next year.

    Conservation Mission Draws Investor Interest

    Beyond de-extinction, Colossal collaborates with governments and research institutions to preserve the genetic material of endangered species. It has also spun off two businesses focused on plastic degradation and DNA analytics, broadening its commercial portfolio. The fundraising effort comes amid growing investor appetite for deep-tech startups, driven by advances in artificial intelligence, biotechnology, and climate innovation.

    Critics Urge Caution

    Despite billions in funding, Colossal remains under close scrutiny from scientists and conservation experts. Some critics argue that bringing back extinct animals generates headlines but does little to address the immediate threats facing living species. Others worry about ecological ripple effects: if genetically engineered animals are reintroduced into current ecosystems, they could disrupt food webs or compete with existing species. Colossal maintains that the technologies developed for de-extinction are also designed to bolster protection programs for species that still exist.

  • MIT Biology Department Highlights: From Stem Cell Research to Enzyme Discoveries

    MIT Biology Department Highlights: From Stem Cell Research to Enzyme Discoveries

    MIT’s Department of Biology continues to push the boundaries of life science research. Recent stories highlight groundbreaking work in stem cell regeneration, enzyme assembly, bacterial defense systems, and the achievements of faculty and alumni. Below is a roundup of the latest news from the department.

    Meet the leader of the Department of Biology’s all-important “kitchen”

    Karen O’Leary, lab associate and acting supervisor in the Glassware Sterilization Facility, has become a cornerstone of the department’s operations.

    QS ranks MIT the world’s No. 1 university for 2026-27

    MIT places first overall for the 15th consecutive year and leads in 12 subject areas.

    Harriet having it all

    Harriet Latham Robinson SM ’61, PhD ’65 reflects on a career at the forefront of molecular biology, spanning Boston, Moscow, and beyond.

    Advancing stem cell research and building the next generation of biologists

    Biology PhD student Giselle Valdes studies stem cell regeneration while mentoring aspiring researchers.

    MIT affiliates win 2026 Breakthrough, New Horizons prizes

    Faculty member Shu-Heng Shao and four MIT alumni are honored by the Breakthrough Prize Foundation.

    Enzymes that assemble into droplets can speed up cellular reactions

    MIT biologists find that highly concentrated droplets help cells keep enzymes organized and control growth signals.

    MIT affiliates elected to National Academy of Sciences for 2026

    Six MIT faculty and 10 additional alumni are recognized for outstanding contributions to research.

    Four from MIT named 2026 Searle Scholars

    Computational neuroscientist Sven Dorkenwald and cell biologist Whitney Henry, along with two alumni, are recognized for early-career research.

    MIT BrainTrust supports neighbors living with brain injuries

    Nearly 100 MIT students participate in a buddy program assisting Boston-area residents.

    Biologist Joey Davis explores how cells build complex structures

    His studies shed light on the assembly instructions governing ribosomes, the critical protein-building machines of the cell.

    Six from MIT awarded 2026 Paul and Daisy Soros Fellowships for New Americans

    The fellowship honors immigrant contributions with $90,000 in graduate study funding.

    MIT affiliates elected to the American Academy of Arts and Sciences for 2026

    Four MIT faculty and 13 alumni are among the new members.

    Two MIT alumnae named 2026 Gates Cambridge Scholars

    Mitali Chowdhury ’24 and Christina Kim ’24 will pursue graduate studies at Cambridge University.

    Professor Michael Laub and MIT alumni named 2025 AAAS Fellows

    The American Association for the Advancement of Science recognizes 21 alumni and Laub.

    Slice and dice: SNIPE defense system

    Newly characterized biological defense system directly protects bacteria by chopping up invading viral DNA.